Company / R&D Expense
Upstream Bio, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$136.8M
FY2025
5-year range
$31.8M / $136.8M
FY2023-FY2025
Trend
+330.2%
vs FY2024
Sector context
#112 of 210
Health Care
What the data says
R&D Expense changed +330% YoY in FY2025, a notable deviation from the 2-year average annual change of +165%.
Based on SEC 10-K filings.
$137M in FY2025.
Improved from $32M to $137M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#112 of 210 in Health CareTop 53% of 210This company $136.8M Sector average $644.1M
▼
-78.8% below sector average
Key checks
Key Insights
- In FY2025, r&d expense increased 330.2% year-over-year.
- Ranks #112 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.68 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.8M | +330.2% |
| FY2024 | $31.8M | +0.0% |
| FY2023 | $31.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026